Akero Therapeutics reports a 39% improvement in cirrhosis patients using EFX. See why AKRO stock is soaring with the ...

Equifax (EFX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Akero's SYMMETRY Phase 2b study showed 50mg EFX achieved 24% cirrhosis reversal in MASH patients, with improvements in liver ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Positive data for Veru Inc.’s enobosarm lend more weight to the potential progress of the company’s body-mass preservation program in patients taking Wegovy (semaglutide). Top-line data of the phase ...

Patients with metabolic dysfunction-associated steotohepatitis (MASH) who are already taking a glucagon-like peptide-1 ...

Akero Therapeutics has hit a home run, reporting statistically significant results in two key 96-week metabolic ...

Inspire Investing LLC boosted its position in shares of Equifax Inc. (NYSE:EFX – Free Report) by 4.2% in the 4th quarter, according to its most recent filing with the Securities and Exchange ...

Below is Validea's guru fundamental report for EQUIFAX INC (EFX). Of the 22 guru strategies we follow, EFX rates highest using our P/B Growth Investor model based on the published strategy of ...

Oakmark Funds, advised by Harris Associates, released its “Oakmark Equity and Income Fund” fourth quarter 2024 investor letter. A copy of the letter can be downloaded here. The fund delivered -0.20% ...